Macrogen operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Macrogen with three other
companies in this sector in South Korea:
Seoulin Bioscience Company Limited
sales of 49.88 billion Korean Won [US$43.84 million]
of which 92%
Medipost Co Ltd
(44.38 billion Korean Won [US$39.01 million]
of which 47%
was Umbilical Cord Blood), and
(25.80 billion Korean Won [US$22.68 million]
of which 54%
During the year ended December of 2018, sales at
Macrogen were 110.30 billion Korean Won (US$96.95 million).
increase of 8.4%
versus 2017, when the company's sales were 101.79 billion Korean Won.
This was the fifth consecutive year of sales increases at Macrogen
(and since 2013, sales have increased a total of 129%).
Sales of Others saw an increase
that was more than double the company's growth rate: sales were up
314.2% in 2018, from
2.19 billion Korean Won to 9.07 billion Korean Won.
Macrogen also saw significant increases in sales in
Genome Application (up 14.4% to 6.37 billion Korean Won)
Not all segments of Macrogen experienced an increase in sales in 2018:
sales of Ces fell 0.1% to 32.42 billion Korean Won.